Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

doi:10.1016/0892-0362(94)90049-3

Neurotoxicology and Teratology

Volume 16, Issue 3, May–June 1994, Pages 277-281

https://doi.org/10.1016/0892-0362(94)90049-3 Get rights and content

Abstract

Administration of reserpine, an inhibitor of vesicular catecholamine storage, differentially reduced the accumulation of MPP+ formed from MPTP in rats and mice. The effects were most pronounced in the adrenal gland for either species. In rats, reserpine decreased striatal and hippocampal MPP+ levels while in mice reserpine did not affect the disposition of MPP+ in the striatum but decreased hippocampal MPP+. The data suggest that mice may be more sensitive to the toxicant because less striatal MPP+ appears to be stored in the reserpine-sensitive storage vesicle.

References (24)

K. Chiba et al.
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Biochem. Biophys. Res. Commun.
(1984)
A.J. Daniels et al.
Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter
J. Biol. Chem.
(1988)
D. Di Monte et al.
Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes
Biochem. Biophys. Res. Commun.
(1988)
M. Herkenham et al.
Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study
Neuroscience
(1991)
J.N. Johannessen et al.
Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects
Life. Sci.
(1985)
J.W. Langston
Neuromelanin-containing neurons are selectively vulnerable in parkinsonism
Trends Pharmacol. Sci.
(1988)
E. Melamed et al.
Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP
Neuropharmacol.
(1985)
M. Naoi et al.
A fluorometric determination of N-methyl-4-phenylpyridinium ion, using high-performance liquid chromatography
Anal. Biochem.
(1987)
J.F. Reinhard et al.
Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP: Evidence for subcellular sequestration as basis for resistance to the toxicant
Neurosci. Lett.
(1988)
J.F. Reinhard et al.
Carrier-independent entry of 1-methyl-4-phenylpyridinium (MPP+) into adrenal chromaffin cells as a consequence of charge delocalization
Biochem. Biophys. Res. Commun.
(1990)

R.S. Burns et al.

A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

C.C. Chiueh et al.

Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey

Psychopharmacol. Bull.

(1984)

Cited by (12)

Manganese mixture inhalation is a reliable Parkinson disease model in rats
2012, NeuroToxicology
Citation Excerpt :
Thus, rats are not recommended for MPTP studies, because rats fail to develop parkinsonian features, as shown, e.g. for monkeys and mice (Schmidt and Ferger, 2001). The evident insensitivity of rats to MPTP toxicity may be related to a species specific metabolism of MPTP and/or sequestration of MPP+, which could be different in rats compared to mice and monkeys (Russo et al., 1994; Schmidt and Ferger, 2001). And despite that MPTP in non-human primates and mice provokes a well animal model, a spontaneous recovery of parkinsonian symptoms has been described in both, monkeys (Eidelberg et al., 1986; Taylor et al., 1997) and mice (Sedelis et al., 2000, 2001) after MPTP administration, which causes concern to use this model for an assessment of long-term therapeutic effects.
Manganese (Mn) is an essential trace metal. Regardless of its essentiality, it has been reported that the overexposure causes neurotoxicity manifested as extrapyramidal symptoms similar to those observed in Parkinson disease (PD). Recently, our group reported that mice that inhaled for 5 months the mixture of manganese chloride (MnCl₂) and manganese acetate Mn(OAc)₃ developed movement abnormalities, significant loss of substantia nigra compacta (SNc) dopaminergic neurons, dopamine depletion and improved behavior with l-DOPA treatment. However, this model has only been characterized in mice. In order to have a well-supported and generalizable model in rodents, we used male Wistar rats that inhaled a mixture of 0.04 M MnCl₂ and 0.02 M Mn(OAc)₃, 1 h three times a week for 6 months. Before Mn exposure, animals were trained to perform motor tests (Beam-walking and Single-pellet reaching tasks) and were evaluated each week after the exposure. The mixture of MnCl₂/Mn(OAc)₃ caused alterations in the motor tests, 75.95% loss of SNc dopaminergic neurons, and no cell alterations in Globus Pallidus or striatum. With these results we conclude that the inhalation of the mixture of Mn compounds is a useful model in rodents for the study of PD.
Susceptibility to a parkinsonian toxin varies during primate development
2012, Experimental Neurology
Citation Excerpt :
Brain samples (0.3–1 mg protein) were sonicated in 200 μl 0.1 M perchloric acid containing 0.4 mM sodium metabisulfite and 0.1 mM EDTA disodium dihydrate (Naoi et al., 1987), and following centrifugation, a 50 μl aliquot was separated by HPLC. The HPLC system was adapted from previous methods (Naoi, et al., 1987; Russo, et al., 1994) and comprised a 4.6 mm × 250 mm Cosmosil 5 C18-MS-II column (Nacalai USA Inc., San Diego, CA), using a pH 7.75 mobile phase (20 mM boric acid, 3 mM tetrabutylammonium sulfate, 0.25 mM hexane sulfonic acid and 7.5% isopropanol) pumped at 0.8 ml/min (Shimadzu LC-10ADVP, Columbia, MD) with native fluorescence detection of MPP+ achieved at excitation/emission wavelengths of 295 and 375 nm (Shimadzu RF-10AXL). Less tailing of the MPP+ peak was obtained with this column compared to other tested reverse-phase columns.
Symptoms of Parkinson's disease typically emerge later in life when loss of nigrostriatal dopamine neuron function exceeds the threshold of compensatory mechanisms in the basal ganglia. Although nigrostriatal dopamine neurons are lost during aging, in Parkinson's disease other detrimental factors must play a role to produce greater than normal loss of these neurons. Early development has been hypothesized to be a potentially vulnerable period when environmental or genetic abnormalities may compromise central dopamine neurons. This study uses a specific parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), to probe the relative vulnerability of nigrostriatal dopamine neurons at different stages of primate development. Measures of dopamine, homovanillic acid, 1-methyl-pyridinium concentrations and tyrosine hydroxylase immunoreactive neurons indicated that at mid-gestation dopamine neurons are relatively vulnerable to MPTP, whereas later in development or in the young primate these neurons are resistant to the neurotoxin. These studies highlight a potentially greater risk to the fetus of exposure during mid-gestation to environmental agents that cause oxidative stress. In addition, the data suggest that uncoupling protein-2 may be a target for retarding the progressive loss of nigrostriatal dopamine neurons that occurs in Parkinson's disease and aging.
The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter
1998, Neuroscience
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces a parkinsonian syndrome in man and experimental animals. The toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenylpyridinium, exhibits high-affinity uptake by plasma membrane monoamine transporters and also by the vesicular monoamine transporter. Using autoradiographic and immunohistochemical methods in mice, we demonstrate the accumulation of [³H]1-methyl-4-phenylpyridinium within neurons that contain the vesicular monoamine transporter, following systemic administration of [³H]1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Within 1–24 h following the intraperitoneal administration of 10 μg/kg of [³H]1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, [³H]1-methyl-4-phenylpyridine labelling was found within such regions as the locus coeruleus, dorsal, medial, and pallidal raphe nuclei, substantia nigra pars compacta, ventral tegmental area, and paraventricular nucleus of the hypothalamus. These regions all contain monoaminergic somata as defined by immunohistochemical staining with an antibody against the vesicular monoamine transporter. There was a positive relationship between the density of [³H]1-methyl-4-phenylpyridinium label and the density of vesicular monoamine transporter immunoreactivity: the highest densities of both were found in the locus coeruleus and lowest densities in the midbrain dopaminergic neurons. In addition, [³H]1-methyl-4-phenylpyridinium labelling was detected in the bed nucleus of the stria terminalis and paraventricular nucleus of the thalamus, which also contained vesicular monoamine transporter immunoreactive nerve terminals.
The present data indicate that low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine cause a significant accumulation of 1-methyl-4-phenylpyridinium within monoaminergic somata in parallel with theamount of vesicular monoamine transporter in the neuron. Since nuclei with intense labelling are not damaged by doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine that are toxic to midbrain dopaminergic neurons, these data are consistent with the hypothesis that sequestration of 1-methyl-4-phenylpyridinium within monoaminergic synaptic vesicles can protect the neurons from degeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Murine models of brain aging and age-related neurodegenerative diseases
1997, Behavioural Brain Research
In the past, structural changes in the brain with aging have been studied using a variety of animal models, with rats and nonhuman primates being the most popular. With the rapid evolution of mouse genetics, murine models have gained increased attention in the neurobiology of aging. The genetic contribution of age-related traits as well as specific mechanistic hypotheses underlying brain aging and age-related neurodegenerative diseases can now be assessed by using genetically-selected and genetically-manipulated mice. Against this background of increased demand for aging research in mouse models, relatively few studies have examined structural alterations with aging in the normal mouse brain, and the data available are almost exclusively restricted to the C57BL/6 strain. Moreover, many older studies have used quantitative techniques which today can be questioned regarding their accuracy.
Here we review the state of knowledge about structural changes with aging in outbred, inbred, genetically-selected, and genetically-engineered murine models. Moreover, we suggest several new opportunities that are emerging to study brain aging and age-related neurodegenerative diseases using genetically-defined mouse models. By reviewing the literature, it has become clear to us that in light of the rapid progress in genetically-engineered and selected mouse models for brain aging and age-related neurodegenerative diseases, there is a great and urgent need to study and define morphological changes in the aging brain of normal inbred mice and to analyze the structural changes in genetically-engineered mice more carefully and completely than accomplished to date. Such investigations will broaden knowledge in the neurobiology of aging, particularly regarding the genetics of aging, and possibly identify the most useful murine models.
Mechanism of delayed convulsion in fish: The actions of norepinephrine in spinal cord
2021, Fishes
Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons
2009, Molecular Neurobiology

View all citing articles on Scopus

View full text

ArticleDifferences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Abstract

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Neuroscience

Life. Sci.

Trends Pharmacol. Sci.

Neuropharmacol.

Anal. Biochem.

Neurosci. Lett.

Biochem. Biophys. Res. Commun.

A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey

Psychopharmacol. Bull.

Article
Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine